Skip to content

Study · Ex vivo tissue · 1994

2 results

Thymosin alpha 1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies: preliminary results.

Eckert K, Schmitt M, Garbin F, Wahn U, Maurer HR

International journal of immunopharmacology1 Dec 1994Cited by 16 (Europe PMC)

PMID7705963 (opens in a new tab)DOI10.1016/0192-0561(94)90081-7 (opens in a new tab)PepBankPUB-07705963
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In cells from patients with common variable immunodeficiency, thymosin alpha‑1 did not affect the moderately reduced LAK-cell activity.

    In plain wordsIn lab tests, thymosin alpha‑1 did not change the reduced killer-cell activity of immune cells in common variable immunodeficiency.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLAK-cell activity in common variable immunodeficiency
    Study

    humann: not reported in source

    Lymphokine-activated killer cells from patients with primary immunodeficiencies
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The moderately reduced LAK-cell activity was not affected by T alpha 1.
    1 context sentence
    Summary · context
    Moreover, the effect of thymosin alpha 1 (T alpha 1) on LAK-cell activity was studied in 11 patients with different immunodeficiencies.
  2. 02LabEx vivo tissueEfficacy outcome

    In cells from other immunodeficient patients, thymosin alpha‑1 in vitro improved LAK-cell activity up to 25-30% in three patients and had no effect in one.

    In plain wordsIn lab tests, thymosin alpha‑1 raised killer-cell activity of immune cells in three of four cases with other immunodeficiencies.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLAK-cell activity in other immunodeficient patients
    Study

    humann: not reported in source

    Lymphokine-activated killer cells from patients with primary immunodeficiencies
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    LAK-cell activity improvement
    25 to 30%
    three patients

    Source sentences

    Summary
    The mean LAK-cell activity could be improved by T alpha 1: three patients showed an improvement of their LAK-cell activity up to 25-30% after T alpha 1 administration in vitro, but in one case T alpha 1 was without any effect.
    1 context sentence
    Summary · context
    Moreover, the effect of thymosin alpha 1 (T alpha 1) on LAK-cell activity was studied in 11 patients with different immunodeficiencies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.